Design and Evaluation of the PLGA Nanoparticles Containing Ketorolac Tromethamine in Glioblastoma Treatment       
Yazarlar (6)
Tuğba Çopur
Hacettepe Üniversitesi, Türkiye
Dr. Öğr. Üyesi Nihat KURT Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Esra Pezik
Hacettepe Üniversitesi, Türkiye
Doruk Yalçın
Koç University, Türkiye
Sibel Bozdağ Pehlivan
Hacettepe Üniversitesi, Türkiye
Levent Öner
Hacettepe Üniversitesi, Türkiye
Makale Türü Özgün Makale
Makale Alt Türü SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale
Dergi Adı Journal of Pharmaceutical Innovation
Dergi ISSN 1872-5120 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Dergi Grubu Q2
Makale Dili İngilizce
Basım Tarihi 07-2025
Cilt No 20
Sayı 4
DOI Numarası 10.1007/s12247-025-10051-2
Makale Linki https://doi.org/10.1007/s12247-025-10051-2
Özet
The blood–brain barrier (BBB) separates blood from brain tissue, making drug delivery to the brain a significant challenge. This study aims to develop and optimize a novel nanoparticle system that may overcome the BBB and have a potential effect on glioblastoma. Ketorolac tromethamine (KT)-loaded poly(lactic-co-glycolic acid) (PLGA) RG 503-H nanoparticles were prepared using water/oil/water (W/O/W) emulsification solvent evaporation. KT-loaded nanoparticles have a particle size of 155.5 ± 2.08 nm, a zeta potential of -12.9 ± 1.23 mV, a polydispersity index of 0.111 ± 0.035, and an encapsulation efficiency of 53.46%. A significant portion of the drug (> 90%) was released in 6 h and completed within 24 h. When 3% (w/v) mannitol and trehalose were used as cryoprotectants, the nanoparticles remained physically stable. Additionally, it has been discovered that KT solution is cytotoxic at high doses to Rat Brain Glioblastoma (RG2) cells, and KT-loaded nanoparticles are more effective than drug solutions at lower doses.
Anahtar Kelimeler
PLGA nanoparticle | Drug delivery | Cryoprotectant | Ketorolac tromethamine | Glioblastoma | Release kinetics